Tuesday, October 20, 2026

by Matt Baker, Physicians Office Resource

A patient arrives with fatigue, a few extra pounds, and a question that primary care physicians hear often: “Could it be my thyroid?”

It is a reasonable question. Thyroid disease can affect energy, weight, mood, bowel habits, and cardiovascular health. But those same complaints fill appointment schedules for reasons that have little to do with thyroid function. Poor sleep, medication effects, depression, and the demands of everyday life can produce a remarkably similar story.

Then the laboratory report arrives. TSH is slightly elevated. Free T4 is normal. The patient wants an answer, and the physician wants to help. Is this the explanation everyone has been looking for—or a finding that deserves a second look before it becomes a permanent diagnosis?

That is where thyroid testing becomes more than ordering a blood test. In primary care, the real work is deciding what the result means for the person sitting across the room.

Before the lab order, listen to the story

The ease of ordering TSH can make it feel like a natural addition to an annual laboratory panel. Yet routine screening and investigating suspected disease are different decisions. The US Preventive Services Task Force continues to find insufficient evidence to determine the balance of benefits and harms of screening asymptomatic, nonpregnant adults. That statement leaves room for judgment, but it does not establish a benefit from testing everyone.¹

A clinical reason for testing gives the result a useful context. Fatigue alone is common. Fatigue accompanied by persistent cold intolerance, constipation, and other suggestive changes creates a stronger case. New atrial fibrillation, unexplained tachycardia, tremor, or weight loss should raise concern for excess thyroid hormone. Previous thyroid treatment, neck irradiation, autoimmune disease, and family history also help shape the decision.^1,2

The history matters especially when disease presents quietly. An older adult with hyperthyroidism may show weight loss, weakness, or cardiac symptoms without the familiar picture of tremor and hyperactivity. Hypothyroid symptoms can disappear into an explanation of “getting older.” A thoughtful approach avoids indiscriminate testing while keeping a treatable disorder on the differential.³

A small flag can carry a large meaning

Laboratory reports make abnormal results easy to spot. They do not make those results equally important. A TSH just outside the reference interval and a substantial elevation accompanied by low free T4 should lead to different conversations.

For most stable outpatients with suspected primary thyroid disease, TSH is a useful starting point. Reflex testing can add free T4 when TSH is elevated, and free T4 plus T3 when it is suppressed. Elevated TSH with low free T4 supports overt primary hypothyroidism; elevated TSH with normal free T4 defines subclinical hypothyroidism. Suppressed TSH with elevated free T4 or T3 indicates thyrotoxicosis.⁴

Those distinctions matter because the word “abnormal” can quickly become “disease,” and “disease” can quickly become “medication.” A reference interval helps interpret a measurement. It does not settle the treatment decision. TSH varies with physiology, age, illness, medications, and laboratory methods. Its distribution shifts upward with age, adding another reason to interpret a modest elevation carefully in an older patient.⁶

Imagine a 76-year-old with fatigue, TSH of 6.2 mIU/L, and normal free T4. The result deserves attention. It also leaves room for other explanations. Reviewing sleep, medications, recent illness, and the broader history while confirming the thyroid finding can prevent the first available answer from becoming the only answer considered.

Sometimes the best next step is another measurement

Repeating a borderline result can feel unsatisfying to a patient who hoped the first test would explain everything. But confirmation has a purpose: it distinguishes a persistent pattern from a temporary change.

For a stable, mild abnormality, reassessment after roughly two to three months is often reasonable, with timing adjusted to the clinical circumstances. More substantial abnormalities, worsening symptoms, or significant thyrotoxicosis require earlier evaluation. The point is to give a borderline finding enough context without allowing consequential disease to wait.^1,2

The interval between tests is also an opportunity to review what might have influenced the result. Acute illness can alter thyroid hormone metabolism and TSH secretion, and recovery can produce temporary changes. Unless thyroid dysfunction is suspected as a contributor to the acute illness, testing during that period may create more confusion than clarity. An unexpected inpatient result may need reassessment after recovery.^6,7

The supplement history deserves a direct question. Patients may not think to mention a hair, skin, and nail product when asked about medications. Biotin can interfere with susceptible assays, producing falsely low TSH and falsely elevated thyroid hormone measurements. That pattern can resemble hyperthyroidism even when thyroid function is normal. Coordinate repeat testing and any interruption of biotin with the laboratory, because the appropriate interval depends on dose, assay, and clearance.^4,6

Amiodarone and lithium can cause genuine thyroid dysfunction; other medications can affect hormone metabolism, TSH secretion, or measurement. When the laboratory picture and the clinical picture do not fit, a conversation with the laboratory may be more useful than another prescription.⁶

The temptation to treat a number

Subclinical hypothyroidism puts the pressure to “do something” into sharp focus. The patient has symptoms, the test has a flag, and levothyroxine seems like a straightforward solution. Whether it will help is a separate question.

In the TRUST trial, 737 adults aged 65 or older with persistent subclinical hypothyroidism received levothyroxine or placebo. Treatment lowered TSH but did not improve hypothyroid symptom or tiredness scores at one year. The trial chiefly informs care of older adults with mild disease. It should not be used to dismiss overt hypothyroidism or applied wholesale to pregnancy or substantially greater TSH elevations.⁸

Treatment decisions should consider persistence, age, symptoms, reproductive status, and the degree of biochemical abnormality. As one guideline example, UK NICE guidance recommends considering levothyroxine for TSH of at least 10 mIU/L on two measurements three months apart. It also permits a six-month treatment trial in selected symptomatic adults younger than 65 with persistent elevations below 10. This is a framework for individualized decisions; recommendations differ across organizations and populations.²

Thyroid antibodies add another layer. A positive thyroid peroxidase antibody result can support autoimmune thyroiditis and help assess progression risk. It does not automatically mean the patient currently needs thyroid hormone. Repeating antibody levels generally adds little to ongoing management.⁹

For patients, that distinction can be difficult: “If I have Hashimoto’s, why aren’t we treating it?” Explaining that treatment replaces deficient hormone, while follow-up tracks whether deficiency develops, gives observation a clear purpose. A plan for reassessment is essential. Without it, watchful waiting can become a result that no one revisits.

Avoiding missed disease takes equal attention

Caution about treating a mildly elevated TSH should not make a persistently low TSH seem harmless. Normal free T4 does not end the evaluation when TSH is suppressed; T3 may reveal a different picture. Review thyroid hormone use, medications, and interference, then determine whether the suppression persists.^4,10

A persistent TSH below 0.1 mIU/L deserves particular attention. ATA guidance recommends treatment of subclinical hyperthyroidism in adults aged 65 or older and in patients with relevant cardiac risk, heart disease, osteoporosis, or hyperthyroid symptoms. The cause matters: Graves disease, autonomous nodules, and thyroiditis do not all call for the same response.¹⁰

Thyroiditis, for example, may release stored hormone rather than increase hormone synthesis. Antithyroid drugs generally do not address that mechanism. Recognizing the difference avoids unnecessary therapy and helps anticipate a possible hypothyroid phase during recovery.¹¹

There is also an important exception to the reassuring normal TSH. When pituitary disease is suspected, TSH alone can miss central hypothyroidism. Patients with pituitary disease, surgery, irradiation, or other suggestive findings need free T4 assessed alongside TSH. Low free T4 with an inappropriately normal, low, or mildly elevated TSH warrants further evaluation. Possible adrenal insufficiency must be assessed before starting levothyroxine in this setting.⁵

These exceptions are worth keeping in mind because under-diagnosis often begins with a result that appears reassuring when viewed alone.

More testing can create more questions

A larger thyroid panel is not necessarily a more informative one. T3 testing has a role in suspected hyperthyroidism, but rarely helps diagnose hypothyroidism. Reverse T3 does not provide a useful routine assessment of thyroid function in stable outpatients. Tests should earn their place by answering a clinical question.⁴

The same principle applies to ultrasound. An isolated abnormal TSH without a palpable abnormality or another structural indication should not routinely lead to imaging. Incidental nodules can start a sequence of surveillance and procedures without explaining the original complaint. Conversely, a normal TSH does not exclude a clinically important nodule. A concerning neck examination needs an appropriate structural evaluation.¹²

Keeping function and structure distinct helps the physician explain why one patient needs blood testing, another needs imaging, and some need both.

Pregnancy changes the conversation

Pregnancy deserves its own approach. Changes in gestational physiology affect thyroid test interpretation, and decisions require pregnancy-specific reference ranges and monitoring. Known thyroid disease should be reviewed before conception when possible and promptly when pregnancy is identified.¹³

The ATA published updated guidance in 2026 addressing preconception, pregnancy, and postpartum thyroid disease. Primary care physicians should use that framework with obstetric and endocrine colleagues. Postpartum thyroiditis also deserves consideration when fatigue and mood changes persist; those symptoms can otherwise blend into the expected demands of caring for a newborn. Evidence supporting conservative management in older adults cannot simply be transferred to pregnancy.¹³

The conversation continues after the prescription

A thyroid diagnosis is not finished when treatment begins. Excess replacement creates its own problems, making follow-up part of responsible prescribing. Thyroid function is generally reassessed about six to eight weeks after levothyroxine initiation or dose changes. TSH usually guides treatment of primary hypothyroidism; central disease requires a different monitoring approach.^3,5,15

Before increasing a dose for an unexpected TSH, ask how the medication is actually taken. Missed doses, food, calcium, and iron can affect exposure. Increasing the prescription and then correcting inconsistent administration can overshoot the intended replacement. Persistent symptoms despite appropriate biochemical treatment should also reopen the broader differential rather than repeatedly drive the dose upward.¹⁴

Patients deserve an explanation of what the results establish and what remains uncertain. “Your thyroid levels do not explain these symptoms” should be followed by a plan to investigate them. “We need to repeat this test” should come with a reason and a timeframe.

That is the balance primary care brings to thyroid testing: attention to the laboratory finding, attention to the patient’s experience, and a plan that connects the two. Done well, the process helps prevent unnecessary diagnoses while giving meaningful thyroid disease the attention it needs.

References

1. US Preventive Services Task Force. Thyroid dysfunction: screening. Published March 24, 2015. Surveillance update August 21, 2024. Accessed October 6, 2026.
2. National Institute for Health and Care Excellence. Thyroid disease: assessment and management. NICE guideline NG145. Published November 20, 2019. Updated October 12, 2023. Accessed October 6, 2026.
3. American Thyroid Association. Older patients and thyroid disease. Accessed October 6, 2026.
4. American Thyroid Association. Thyroid function tests. Accessed October 6, 2026.
5. Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888-3921. doi:10.1210/jc.2016-2118
6. Van Uytfanghe K, Ehrenkranz J, Halsall D, et al. Thyroid stimulating hormone and thyroid hormones (triiodothyronine and thyroxine): an American Thyroid Association-commissioned review of current clinical and laboratory status. Thyroid. 2023;33(9):1013-1028. doi:10.1089/thy.2023.0169
7. National Institute for Health and Care Excellence. Indications for testing: evidence review B. Thyroid disease: assessment and management. 2019. Accessed October 6, 2026.
8. Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376(26):2534-2544. doi:10.1056/NEJMoa1603825
9. American Thyroid Association. Hashimoto’s thyroiditis. Accessed October 6, 2026.
10. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229
11. American Thyroid Association. Thyroiditis. Accessed October 6, 2026.
12. Moorthy R, Balasubramanian SP, Farnell K, et al. Evaluation and management of thyroid nodules: a joint consensus statement from the British Thyroid Association (BTA), British Association of Endocrine and Thyroid Surgeons (BAETS) and collaborating bodies. Clin Endocrinol (Oxf). 2026;104(6):682-692. doi:10.1111/cen.70116
13. Korevaar TIM, Leung AM, Alexander EK, et al. American Thyroid Association 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum. Thyroid. 2026;36(5):481-544. doi:10.1177/10507256261445624
14. American Thyroid Association. Thyroid hormone treatment. Accessed October 6, 2026.
15. American Thyroid Association. Hypothyroidism. Accessed October 6, 2026.